Table 1. Participant characteristics.
| Characteristic | Control (n = 310) | Case (n = 155) |
|---|---|---|
| Age (mean, SD) | 31.9 (7.8) | 30.6 (7.8) |
| Gender | ||
| Male | 264 (85.2%) | 142 (91.6%) |
| Female | 46 (14.8%) | 13 (8.4%) |
| Country | ||
| Australia | 4 (1.3%) | 2 (1.3%) |
| Brazil | 12 (3.9%) | 6 (3.9%) |
| Canada | 14 (4.5%) | 7 (4.5%) |
| Dominican Republic | 2 (0.6%) | 1 (0.6%) |
| Haiti | 4 (1.3%) | 2 (1.3%) |
| Peru | 68 (21.9%) | 34 (21.9%) |
| USA | 206 (66.5%) | 103 (66.5%) |
| Race and Ethnicity * | ||
| White | 152 (49.0%) | 79 (51.0%) |
| Black | 43 (13.9%) | 15 (9.7%) |
| Multiracial or Other Race | 12 (3.9%) | 11 (7.1%) |
| Mestizo/a | 68 (21.9%) | 34 (21.9%) |
| Hispanic | 35 (11.3%) | 16 (10.3%) |
| Vaccine trial treatment arm | ||
| Intervention | 177 (57.1%) | 86 (55.5%) |
| Comparison | 133 (42.9%) | 69 (44.5%) |
| AD5 Titer stratum | ||
| >18 | 176 (56.8%) | 84 (54.2%) |
| < = 18 | 134 (43.2%) | 71 (45.8%) |
| Behavioral Risk score (mean, SD) ** | 2.8 (1.2) | 3.3 (1.2) |
| Circumcised (male participants) | 157 (59.5%) | 84 (59.2%) |
| HSV-2 seropositive (male participants) | 81 (30.7%) | 57 (40.1%) |
*Race and ethnicity were asked in a singular question about self-identity in the parent study without option of multiselect; options including race or ethnicity therefore sum to 100%.
**Combined risk score for male and female includes theoretical and observed range 0–7 points.